Last reviewed · How we verify
GP2013 - A Proposed biosimilar rituximab
GP2013 is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity.
GP2013 is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity. Used for Rheumatoid arthritis, Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia.
At a glance
| Generic name | GP2013 - A Proposed biosimilar rituximab |
|---|---|
| Sponsor | Sandoz |
| Drug class | Monoclonal antibody (CD20 inhibitor) |
| Target | CD20 |
| Modality | Biologic |
| Therapeutic area | Immunology, Oncology |
| Phase | Phase 3 |
Mechanism of action
As a biosimilar of rituximab, GP2013 targets the CD20 antigen expressed on the surface of B lymphocytes. Upon binding, it triggers B cell destruction through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), thereby reducing pathogenic B cell populations in autoimmune and hematologic conditions.
Approved indications
- Rheumatoid arthritis
- Non-Hodgkin's lymphoma
- Chronic lymphocytic leukemia
- Granulomatosis with polyangiitis
- Microscopic polyangiitis
Common side effects
- Infusion reactions
- Infections
- Neutropenia
- Anemia
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GP2013 - A Proposed biosimilar rituximab CI brief — competitive landscape report
- GP2013 - A Proposed biosimilar rituximab updates RSS · CI watch RSS
- Sandoz portfolio CI